Skip to content

Music and expressive arts therapy for women with a history of gynaecological cancer

A randomised controlled trial for women with a history of gynaecological cancer assessing the feasibility, experiences and potential effectiveness of receptive music therapy (KMR) and expressive arts therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN50156343
Enrollment
60
Registered
2012-04-03
Start date
2012-04-02
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fear of recurrence in gynaecological cancer patients Cancer

Interventions

A short-term intervention called KMR will be implemented. KMR (Short Music Journeys) is a receptive form of music therapy that includes the uses of expressive arts techniques (EXA) (especially drawing
the patient will be randomised to either individual treatment or the wait-list group. Individual KMR/EXA Therapy (Group A): The procedure starts with one interview session, followed by twelve weekly

Sponsors

Aalborg University (Denmark)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Women with a history of gynaecological cancer 2. At follow-up at the Department of Gynaecological Oncology, Karolinska University Hospital, Stockholm, Sweden, 3-24 months after primary treatment 3. 18-75 years 4. Fluent in written and spoken Swedish language

Exclusion criteria

Exclusion criteria: 1. Relapse 2. High risk of relapse during the study period 3. A history of mental disorder or substance abuse 4. > 75 years

Design outcomes

Primary

MeasureTime frame
1. Reduced fear of recurrence 2. Improved sexual health 3. Improved integration of body-image 4. Improved existential health and well-being The evaluation of these symptoms will be assessed through detailed self-evaluation questionnaires, specifically constructed and validated for this population, and two standardised questionnaires [EORTC QLQ-C30, Montgomery?Åsberg Depression Rating Scale (MADRS)] Measured at: Group A, Intervention group (individual treatment): T0 Screening (0 months) T1 Baseline (0 months) T2 End of treatment (C:a 5 months) T3 Follow-up (C:a 8 months after baseline) Group B, wait-list group (later group-intervention): T0 Screening (0 months) T1 Baseline (0 months) T2 End of wait-list, before group-intervention (C:a 5 months) T3 End of treatment (C:a 8 months after baseline) T4 Follow-up (C:a 11 months after baseline)

Secondary

MeasureTime frame
1. Experience and change of quality of life 2. Experiences of cancer treatment 3. Experiences of and change in self-care 4. Experience of information and care from health care personnel 5. Experiences of and changes in body- and self-image, self-esteem and confidence 6. Experiences of and changes in feelings of guilt and shame 7. Experiences of and changes in social interactions and networking 8. Experiences of and changes in practices of cultural events, music and art, and hobbies 9. Experiences of and changes in practices of journal writing and expressive writing 10. Experience of and change in coping strategies 11. Previous experiences of sexual abuse 12. Previous experiences of traumatic life events 13. Experiences of participation in a music therapy study (specific questions in the questionnaire and in qualitative interviews with samples of participants and therapists) 14. Acceptability and feasibility of our methodology (specific questions in the questionnaires and in qualitative interviews with samples of participants) 15. Drop-out analysis: 15.1. Exclusions 15.2. Recruitment rates 15.3. Loss to follow-up 15.4. Drop-outs (group therapy after wait-list) 15.5. Missing data Measured at: Group A, Intervention group (individual treatment): T0 Screening (0 months) T1 Baseline (0 months) T2 End of treatment (C:a 5 months) T3 Follow-up (C:a 8 months after baseline) Group B, wait-list group (later group-intervention): T0 Screening (0 months) T1 Baseline (0 months) T2 End of wait-list, before group-intervention (C:a 5 months) T3 End of treatment (C:a 8 months after baseline) T4 Follow-up (C:a 11 months after baseline)

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026